Ann Meulemans, Phd, Cdo
Managing Partner at 2 Bridge CVBA
pharmaceutical
AmatsiSEPSÂ
Portugal
Biography
Yves Gonnissen founded SEPS Pharma in 2007 and successfully completed a seed capital round in 2008 led by The Investment Company for Limburg. Since the company’s foundation he incorporated a hybrid business model combining internal product development programs and drug product development services. In 2002 he started his professional career at Janssen Pharmaceutica (a subsidiary of Johnson & Johnson). As a pharmaceutical product developer he was involved in formulation and process development via spray drying of Intelence®, a novel NNRTI HIV drug. Yves holds a Master’s degree in Bioscience Engineering (Chemistry) from the University of Leuven in Belgium. He obtained his PhD at Ghent University in Belgium where he pursued his research interests in the fields of pharmaceutical technology and pharmaceutical drug product development. In 2015 SEPS Pharma was acquired by Amatsigroup and changed its name to AmatsiSEPS.
Research Interest
Drug development
